

Press release from Emotra AB (publ)
Göteborg, September 21, 2015

Conference with 15 clinics in Rome

On September 16–17, Emotra held a very successful conference with 15 of the psychiatric clinics that are participating in our ongoing European, clinical multi-centre study. We established that 780 tests have now been carried out and analysed. The participating clinics estimated that they will be submitting an equivalent amount of tests to Emotra for analysis during the remaining months of this year. Our forecast indicates that we will be able to conclude our study in the December 2016 – February 2017 time frame.

In connection with this successful conference, which professor Marco Sarchiapone and his colleagues had arranged, a proposal was forwarded about using the comprehensive clinical data collected during the course of this trial to carry out a number of further studies with the aim of increasing our knowledge of the connection between various populations and suicide, but also to study the connection between hyporeactivity and other specific conditions. From Emotra's point of view, this proposal provides a positive opportunity as it increases the motivation to conduct tests with EDOR.

The participants agreed to arrange a satellite conference in Madrid in connection with a large, international convention being held on March 12–15, 2016. Furthermore, another group conference will be arranged in connection with an important international convention in Oviedo, Spain, on September 8–10, 2016. The ambition for our Oviedo meeting is to compile preliminary results concerning the patients that we up until that point have been able to follow for 12 months after testing. No decision has yet been made concerning the publication of those preliminary results.

Once we have completed our study and the statistical processing of the study data has been completed, we will summon a consensus meeting where the group shall decide how EDOR should be used in routine clinical operations in the future.

In sum, the conference in Rome has shown that all of the participating clinics are positive to the use of EDOR Test. Furthermore, they are unanimous in the view that the method works very well and that the testing procedure is both quick and easy to carry out. Their opinion is that the study could lead to a recommendation that the test be used in connection with depression, but that there could be other specific groups for which the test is less useful. One of the purposes of the study is to determine any such groups. No actual contraindications have yet been observed.

For further information, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se